IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling by Cheng Chen & Xuejun Zhang
Chen and Zhang  J Transl Med  (2017) 15:42 
DOI 10.1186/s12967-017-1147-2
RESEARCH
IRE1α-XBP1 pathway promotes 
melanoma progression by regulating IL-6/STAT3 
signaling
Cheng Chen and Xuejun Zhang*
Abstract 
Background: The IRE1α-XBP1 pathway is the most conserved branch of the unfolded protein response pathways, 
which are activated during endoplasmic reticulum (ER) stress caused by the accumulation of unfolded/misfolded 
proteins in the ER lumen. The IRE1α-XBP1 pathway plays a critical role in various cancers. However, the role of this 
pathway in melanoma cell growth remains unclear.
Methods: Sixty-one pairs of melanoma specimens and corresponding normal tissues from patients were stained 
with XBP1. Then, XBP1 splicing levels were detected in human tissues and cell lines at the mRNA level. IL-6 expression 
levels were determined in both melanocytes (HEMn-MP) and melanoma cells (Mel-RMu) overexpressing the spliced 
form of XBP1 (XBP1s). IL-6 expression was also examined in 4μ8C-treated HEMn-MP and Mel-RMu cells overexpressing 
IRE1α. Next, we analyzed potential XBP1s binding sites within the IL-6 promoter and conducted ChIP experiments. 
IL-6/STAT3 signaling was detected by western blotting. Melanoma cell proliferation was examined by CCK8 and BrdU 
assays.
Results: The mRNA and protein expression levels of XBP1s were significantly elevated in human melanoma tissues 
and cell lines compared with normal tissues or melanocytes, thus indicating the activation of the IRE1α-XBP1 branch 
in melanoma. Ectopic expression of IRE1α or XBP1s robustly enhanced IL-6 expression in HEMn-MP and Mel-RMu cells. 
Moreover, the inhibition of the RNase activity of IRE1α also abolished the effect of IRE1α in promoting IL-6 expression. 
Mechanistically, XBP1 binds the IL-6 promoter and activates its expression. Furthermore, secreted IL-6 functions in an 
autocrine/paracrine manner, activates the intracellular JAK/STAT3 pathway and promotes the proliferation of mela-
noma cells.
Conclusion: Our results reveal that the IRE1α-XBP1 pathway regulates Mel-RMu cell proliferation and progression by 
activating IL-6/STAT3 signaling.
Keywords: Melanoma, Proliferation, UPR, IRE1α, XBP1, IL-6, STAT3
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Melanoma, one of the most malignant tumors, is increas-
ing in incidence worldwide. However, there is still no 
curative treatment after the disease has spread beyond 
the primary site, owing to the proliferative ability of 
the cells [1]. Melanoma is infamous for its rapid prolif-
eration rate [2], but until now, the exact mechanisms for 
the rapid proliferation of melanoma cells has remained 
unknown [3]. Because of poor vascularization and high 
proliferation rates, melanoma is subjected to many forms 
of stress. Unsurprisingly, these types of stress, including 
hypoxia, nutrient deprivation and altered pH, result in 
the accumulation of unfolded and/or misfolded proteins 
in the endoplasmic reticulum (ER) lumen and cause ER 
stress. This stress induces the activation of the unfolded 
protein response (UPR), which restores ER homeostasis, 
thus leading to cells producing more proteins for neo-
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may assist in several aspects of tumor biology, including 
tumorigenesis, apoptotic evasion, metastasis, angiogen-
esis and chemotherapy resistance [3–6].
The UPR of mammalian cells is initiated by three ER 
transmembrane proteins: activating transcription factor 6 
(ATF6), inositol-requiring enzyme 1 (IRE1), and double-
stranded RNA-activated protein kinase-like ER kinase 
(PERK), which act as proximal sensors of ER stress. 
Under normal conditions, the luminal domains of these 
sensors are occupied by the ER chaperone glucose-regu-
lated protein 78 (GRP78). Under ER stress, sequestration 
of GRP78 by unfolded proteins activates these sensors by 
inducing the phosphorylation and homodimerization of 
IRE1 and PERK along with the relocalization of ATF6 to 
the Golgi, where it is cleaved by Site 1 and 2 proteases, 
thus leading to its activation as a transcriptional factor 
[7–9]. After its activation, IRE1 catalyzes the non-con-
ventional splicing of the mRNA encoding X-box-binding 
protein 1 (XBP1) by removing a 26 nt intron, thereby 
producing an active spliced form (XBP1s), thus initiating 
an essential UPR program [10].
A growing number of studies report that UPR is acti-
vated in various solid tumors; e.g., GRP78 expression is 
elevated in some cancers, including melanoma [11–13]. 
The spliced form of XBP1 is frequently expressed in 
melanoma cell lines and in fresh melanoma isolates [13]. 
Recently, it has been shown that UPR is be activated 
during early stages of melanoma initiation by the onco-
genic form of HRAS (HRASG12V) [14]. The magnitude 
of the nascent protein production is higher in melanoma 
cell lines and results in the activation of UPR pathways, 
including the IRE1α-XBP1 branch [3, 4, 6].
The activation of signal transducer and activator of 
transcription 3 (STAT3) is usually transient in normal 
cells, but STAT3 has been reported to be present in a 
constitutively activated state and to promote tumo-
rigenesis by enhancing cell proliferation, survival, and 
angiogenesis while suppressing the anticancer immune 
response in many different types of cancers, including 
colon cancer, melanoma and myeloma [15–17]. In some 
studies of lymphoid malignancies, interleukin-6 (IL-6) 
has been found to act in an autocrine/paracrine man-
ner and to provide crucial survival signals by activating 
STAT3 signaling [17].
Here, we report that the IRE1α-XBP1 branch is acti-
vated and that the spliced form of XBP1 (XBP1s) is 
increased in human melanoma tissues. Compared with 
normal melanocytes, six melanoma cell lines showed 
higher XBP1 splicing and enhanced IL-6 expression. 
Ectopic expression of IRE1α or XBP1s gave rise to IL-6 
expression, which in turn promoted Mel-RMu cell prolif-
eration, whereas these effects were blocked by IL-6 anti-
bodies. Further experiments revealed that XBP1s directly 
bound to the IL-6 promoter and drove its expression. 
Our study reveals the crucial role of the IRE1α-XBP1 




Clinical data, including age, sex, and the primary mela-
noma site, were collected retrospectively from patient 
records and their pathology reports. All patients were 
diagnosed with melanoma by the Department of Pathol-
ogy, Zhongshan Hospital, Fudan University. In total, 
61 patients were evaluated, and clinical and patho-
logical data were analyzed for each patient. Of these 
patients, the youngest was 30  years old, and the oldest 
was 85  years old. The average age was 57.9  years, and 
the median age was 59  years. Thirty-six patients were 
male, and 25 patients were female. The primary sites of 
melanoma were grouped as head and neck, trunk and 
limbs, of which 75.41% were in the limbs (Table 1). All 
of the tumors were without regional or distant metas-
tasis. The tissue sample collection was approved by the 
Ethics Committee of Zhongshan Hospital, Fudan Uni-
versity, and informed consent was obtained from all 
subjects. The tissue slides were prepared from biopsy 
paraffin blocks. The experiments were carried out under 
approved guidelines and complied with the 1975 Decla-
ration of Helsinki.
Immunohistochemical analysis
Immunohistochemistry was conducted by using anti-
human antibodies against XBP1s (1:100, BioLegend, San 
Diego, CA, USA). The TMA slides stained with XBP1s 
were evaluated by light microscopy at 200× magnifica-
tion by two investigators blinded to the clinicopathologic 
data of the patients. To access the expression intensity 
of XBP1s, the integrated absorbance in the area of a 
Table 1 Clinical characteristics of patients with melanoma
Characteristics No. (%)
Age
 ≤40 9 (14.75)
 40–60 24 (39.34)
 ≥60 28 (45.91)
Sex
 Male 36 (59.02)
 Female 25 (40.98)
Primary sites of melanoma
 Head and face 3 (4.92)
 Trunk 12 (19.67)
 Limbs 46 (75.41)
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1-mm-diameter cylinder was measured by using Image-
Pro Plus version 6.0 (Media Cybernetics, Inc., Rockville, 
MD USA). The mean XBP1s density was calculated as the 
product of the integrated absorbance to total area. The 
tissue slides were prepared from biopsy paraffin blocks. 
The methods were carried out under the approved guide-
lines and complied with the 1975 Declaration of Helsinki.
Cell culture
Melanocyte cell lines (HEMn-MP and HEMn-DP) and 
melanoma cell lines (Mel-RMu, MM200, Mel-CV, IgR3, 
A2058, and SkMel-28) were obtained from the Cell Bank 
of Shanghai, Chinese Academy of Sciences (Shanghai, 
China). All of the cell lines were cultured in high-glu-
cose DMEM supplemented with 10% fetal bovine serum 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA).
Quantitative real‑time PCR
Real-time PCR analyses were performed as previously 
described [18, 19]. Briefly, total RNA of the cells was 
extracted using TRIzol reagent (Invitrogen, Waltham, 
MA, USA) according to the manufacturer’s protocol. 
Then, the RNA was reverse transcribed with an M-MLV 
first-strand cDNA synthesis kit (Invitrogen). Indicated 
mRNA levels were determined by qPCR using SYBR 
Premix Ex Taq (Roche, Basel, Switzerland), and human 
GAPDH was used as an internal control.
Western blotting
Western blotting analysis was performed as previously 
described [20–22]. In brief, cells were harvested and lysed 
in RIPA lysis buffer. Then, proteins were separated by 
SDS-PAGE and transferred to polyvinylidene difluoride 
membranes. The membranes were washed in TBST, 
blocked in 10% milk, and then incubated with primary 
antibodies against human IRE1α (1:1000, Cell Signaling 
Technology, Boston, USA), XBP1s (1:500, BioLegend, San 
Diego, CA, USA), pSTAT3 (1:1000, Cell Signaling Tech-
nology), STAT3 (1:1000, Cell Signaling Technology) or 
GAPDH (1:5000, Abcam, Cambridge, UK) overnight at 
4 °C, and this was followed by incubation with horserad-
ish peroxidase-conjugated secondary antibodies. Pro-
teins were detected with enhanced chemiluminescence 
assay (Thermo Fisher Scientific).
CCK8 and BrdU assays
CCK8 assays were used to detect the effect of XBP1s on 
cell proliferation. Briefly, 1  ×  103 cells were seeded in 
96-well culture plates, and these cells were then incu-
bated with a CCK8 reagent for 2 h at 37 °C at the 24, 48, 
72, 96 and 120 h time points. The staining intensity in the 
medium was measured by determining the absorbance at 
450 nm.
BrdU assays were conducted by using a BrdU Cell Pro-
liferation Assay Kit (#6813, Cell Signaling Technology, 
USA) according to the manufacturer’s instructions.
Luciferase reporter assay
The pGL3 basic plasmid containing the promoter of the 
human interleukin-6 gene, which corresponds to the 
region from −2000 to +100 nt on the putative transcrip-
tion start site (denoted nucleotide +1), was constructed. 
The deletion of the ACGT core from the IL-6 promoter 
was performed by using a PCR-based strategy. HEK293T 
cells were co-transfected with the designed plasmids. 
Luciferase activity was measured using a Dual-luciferase 
Assay Kit (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. Renilla luciferase activity 
was used as an internal control for normalization.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed with an Agarose ChIP Kit 
(Pierce, Cat# 26156, Thermo Fisher Scientific), accord-
ing to the manufacturer’s instructions. In brief, 293T cells 
were subjected to cross-linking with 1% formaldehyde, 
and glycine solution was then added to stop the cross-
linking process. Nuclear extracts were prepared. Chro-
matin-XBP1s complexes were immunoprecipitated with 
anti-Flag (Sigma, Cat# F3165; diluted 1: 500, St. Louis, 
MO, USA) or anti-XBP1s (BioLegend, Cat# 647501; 
diluted 1:100) antibodies by incubation at 4 °C overnight, 
and this was followed by incubation with beads from the 
Agarose ChIP Kit (Pierce) or Protein G-Sepharose beads 
(GE Health, Chicago, IL, USA) at 4 °C for 1 h with gentle 
rocking. After the beads were washed 5 times with wash 
buffer, the complexes were eluted from the beads with 
elution buffer and subjected to PCR analysis.
Statistical analysis
All experiments presented in this paper were repeated 
more than three times. The data are presented as the 
mean ± standard error of mean (s.e.m.). Statistical anal-
ysis (SPSS 18.0 software, SPSS Inc., Armonk, NY, USA) 
was performed with two-tailed independent Student’s t 
tests after a demonstration of homogeneity of variance 
with the F test or one-way ANOVA for more than two 
groups. Scheffe tests were used for post hoc analysis. The 
threshold for statistical significance was set at P < 0.05.
Results
Immunohistochemical staining to determine XBP1s 
expression in human melanoma tissues
To investigate the expression of XBP1s in human mela-
noma, immunohistochemical staining for XBP1s was 
conducted on a melanoma TMA containing 61 pairs of 
melanoma specimens and corresponding normal tissues. 
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Compared with those in normal tissues, significantly 
enhanced protein levels of XBP1s were observed in mel-
anoma tissues, thus indicating hyperactivation of the 
IRE1α-XBP1 pathway in human melanoma.
The IRE1/XBP1 pathway regulates interleukin‑6 expression 
in melanocytes and melanoma cell lines
The results shown in Fig. 1 indicate that the IRE1α-XBP1 
pathway is constitutively activated in human melanoma 
tissues. To investigate the splicing level of XBP1 in mela-
noma cells, we analyzed mRNA levels of the spliced form 
of XBP1 (XBP1s) in a group of cell lines containing nor-
mal melanocytes (HEMn-MP and HEMn-DP) and mela-
noma cells (Mel-RMu, MM200, Mel-CV, IgR3, A2058 
and SkMel-28). Compared with that in HEMn-MP and 
HEMn-DP cells, higher levels of XBP1u (unspliced XBP1) 
mRNA were spliced into XBP1s (spliced XBP1) and then 
translated into the active form of the protein in the mela-
noma cells, thus indicating constitutive activation of the 
IRE1α-XBP1 branch in melanoma cell lines (Fig. 2a).
In agreement with results from previous studies, the 
magnitude of nascent protein production was found 
to be higher in the melanoma cell lines than in the 
melanocytes, thus potentially leading to the activation of 
UPR pathways, including the IRE1α-XBP1 branch [3, 4, 
6].
Next, we overexpressed XBP1s in melanocytes 
(HEMn-MP) and melanoma cells (Mel-RMu). As shown 
in Fig.  2b, c, IL-6 expression levels were dramatically 
increased in XBP1s—overexpressing HEMn-MP (Fig. 2b) 
and Mel-RMu (Fig. 2c) cells.
We then sought to determine whether IRE1α, the cen-
tral mediator in the XBP1 splicing process, is involved in 
the regulation of IL-6 expression in melanoma. IRE1α was 
ectopically expressed in HEMn-MP and Mel-RMu cells 
(Fig.  2d). Owing to the excess accumulation of IRE1α, 
which leads to trans-autophosphorylation and activation 
of the RNase activity of the protein, XBP1 splicing levels 
were dramatically increased in the IRE1α-overexpressing 
HEMn-MP and Mel-RMu cells (Fig. 2e) but were blocked 
by the addition of 4μ8C, a specific inhibitor of the RNase 
activity of IRE1α (Fig.  2e). Moreover, with the increase 
in the level of the spliced form of XBP1, IL-6 expression 
was strongly enhanced in the IRE1α-overexpressing cells 
and was impaired after treatment with 4μ8C (Fig.  2f ). 
Together, these results demonstrate that the upregulation 
Fig. 1 Expression of XBP1s in human melanoma samples. a Representative images and b integrated optical density (IOD) analysis of the immuno-
histochemical images of melanoma tissues and paired normal skin tissues from 61 melanoma patients. c XBP1 splicing levels were analyzed by real-
time PCR in both melanoma tissues and normal skin tissues. The data are presented as the mean ± s.e.m., and P value was analyzed by Student’s t 
test and labeled
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of IRE1α and XBP1s activates the expression of IL-6 in 
HEMn-MP and Mel-RMu cells.
XBP1s activates IL‑6 expression by binding to the IL‑6 
promoter in melanoma cells
To investigate whether XBP1s drives the transcription 
of IL-6 in melanoma cells, we analyzed the promoter 
sequences of human, rat and mouse IL-6 and identified a 
conserved putative UPR element containing the “ACGT” 
core sequence (Fig. 3a), a potential XBP1s binding site [23].
Next, ChIP experiments were conducted to address 
the exact mechanism(s). With an ectopic expression 
of XBP1s, antibodies specific to the flag-tagged XBP1s 
protein co-immunoprecipitated the IL-6 promoter 
regions in Mel-RMu cells (Fig. 3b). Accordingly, the dele-
tion of the “ACGT” core sequence in the IL-6 promoter 
(IL-6Δ) led to loss in the ability of exogenous XBP1s to 
interact with the DNA containing the IL-6 promoter in 
293T cells (Fig. 3c). Furthermore, the results of luciferase 
reporter assays performed in 293T cells showed that 
ectopically expressed XBP1s robustly induced the tran-
scriptional activity of the IL-6 promoter; however, this 
effect was abolished in the IL-6 promoter without the 
“ACGT” core sequence (Fig.  3d). These results demon-
strate that XBP1s binds directly to the IL-6 promoter and 
activates its transcription.
Fig. 2 IRE1α-XBP1 pathway regulates interleukin-6 expression in melanocytes and melanoma cells. a XBP1 splicing levels in melanocytes (HEMn-
MP and HEMn-DP) and melanoma cells (Mel-RMu, MM200, Mel-CV, IgR3, A2058 and SkMel-28). mRNA levels of XBP1s and IL-6 as determined by 
real-time PCR in HEMn-MP (b) and Mel-RMu (c) cells transfected with plasmids pCMV-XBP1s (XBP1s) or pCMV (ctrl.). d The IRE1α protein levels were 
determined by immunoblotting in both HEMn-MP and Mel-RMu cells transfected with plasmids pCMV-IRE1α (IRE1) or pCMV (ctrl.). XBP1 splicing 
(e) and IL-6 (f) expression levels were determined by real-time PCR in IRE1α-overexpressing HEMn-MP and Mel-RMu cells with 4μ8C treatment. The 
results are from at least three independent experiments. The data are presented as the mean ± s.e.m. *P < 0.05, **P < 0.01 by Student’s t test or two-
way ANOVA
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The IRE1α‑XBP1 branch promotes melanoma cell 
proliferation by regulating IL‑6/STAT3 signaling
To investigate the effect of upregulated IL-6 induced by 
the activation of the IRE1α-XBP1 branch, we evaluated 
the phosphorylation levels of STAT3 in Mel-RMu cells 
with IRE1α or XBP1s overexpression. Strikingly, a robust 
increase in STAT3 phosphorylation was observed in 
cells with upregulated IRE1α (Fig. 4a) or XBP1s (Fig. 4c). 
To determine whether the increase in phosphorylated 
STAT3 was caused by extracellular IL-6 secreted by 
melanoma cells, we applied IL-6 antibodies to neutral-
ize IL-6 in the medium. Interestingly, the addition of 
anti-IL-6 antibodies did not disturb the protein levels 
of IRE1α (Fig. 4a) and XBP1s (Fig. 4c) and did not affect 
IRE1α-mediated XBP1 splicing (Fig. 4b) but almost com-
pletely abolished the increase in STAT3 phosphoryla-
tion induced by the overexpression of IRE1α (Fig. 4a) or 
XBP1s (Fig. 4c) in Mel-RMu cells. These data suggested 
that the IRE1α-XBP1 pathway regulates the activation of 
STAT3 signaling by promoting IL-6 secretion by mela-
noma cells.
Many studies have revealed the critical role of IL-6/
STAT3 signaling in regulating cell proliferation and tissue 
regeneration [15–17]. Hence, we sought to evaluate the 
role of the IRE1α-XBP1 branch in melanoma cell prolifer-
ation by performing CCK8 and BrdU assays in Mel-RMu 
cells. The results are shown in Fig.  4d–g. The prolifera-
tion rate of IRE1α-overexpressing cells was much higher 
than that of control cells, but proliferation was blocked 
by the addition of IL-6 antibodies (Fig. 4d, e). A similar 
phenomenon was observed in XBP1s-overexpressing 
melanoma cells (Fig.  4f, g). Together, our data revealed 
that the crucial role of the IRE1α-XBP1 branch in pro-
moting Mel-RMu cell proliferation is exerted by regulat-
ing IL-6/STAT3 signaling.
Discussion
UPR pathways, including the IRE1α-XBP1 branch, have 
been shown to have critical functions in the develop-
ment of melanoma, but the exact mechanisms have been 
unclear. In our present work, we found that XBP1s levels 
were dramatically elevated in human melanoma tissues 
Fig. 3 XBP1 activates IL-6 expression via binding to the IL-6 promoter in melanoma cells. a Sequence alignment of the putative UPR element of 
the Il-6 promoter from humans, rats and mice. The ACGT core is indicated in bold. b Mel-RMu cells were transfected with plasmids expressing Flag-
tagged XBP1s or control (ctrl.). Chromatin immunoprecipitation (ChIP) was performed by using control IgG or anti-Flag antibody before PCR ampli-
fication of the indicated region of the IL-6 promoter. c ChIP assays of extracts from 293T cells co-transfected with the empty vector or pCMV-XBP1s 
plasmid together with the IL-6 or IL-6 without the ACGT core (IL-6Δ) promoter constructs, using anti-XBP1s antibody. d Luciferase reporter assays 
were performed in 293T cells cotransfected with pCMV-XBP1s plasmid together with Luc constructs under the control of the wild-type (WT) human 
IL-6 promoter or that with the ACGT core deleted (IL-6Δ). The results are from at least three independent experiments. The data are presented as the 
mean ± s.e.m. *P < 0.05, **P < 0.01 by two-way ANOVA
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Fig. 4 IRE1α-XBP1 pathway promotes melanoma cell proliferation by regulating IL-6/STAT3 signaling. a Immunoblotting analysis of the indicated 
proteins and b XBP1 splicing levels, as determined by real-time PCR in Mel-RMu cells transfected with plasmids pCMV-IRE1α (IRE1) or pCMV (ctrl.) 
and treated with anti-IL-6 antibodies (anti-IL-6). c Immunoblotting analysis of the indicated proteins in Mel-RMu cells transfected with plasmids 
pCMV-XBP1 (XBP1s) or pCMV (ctrl.) and treated with anti-IL-6 antibodies (anti-IL-6). d, e Cell proliferation was analyzed by CCK8 assay (d) and BrdU 
assay (e) in Mel-RMu cells transfected with plasmids pCMV-IRE1α (IRE1) or pCMV (ctrl.) and treated with anti-IL-6 antibodies (anti-IL-6). f, g Cell 
proliferation analyzed by CCK8 assay (f) and BrdU assay (g) in Mel-RMu cells transfected with plasmids pCMV-XBP1 (IRE1) or pCMV (ctrl.) and treated 
with anti-IL-6 antibodies (anti-IL-6). The results are from more than three independent experiments. The data are presented as the mean ± s.e.m. 
*P < 0.05, **P < 0.01 by Student’s t test, one-way or two-way ANOVA relative to the ctrl. group; #P < 0.05 by Student’s t-test relative to IRE1 + anti-IL6 
or XBP1s + anti-IL6 groups, as indicated
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and melanoma cell lines compared with normal tissues 
or melanocytes. Ectopic expression of IRE1α and XBP1s 
in melanocytes and melanoma cells increased IL-6 lev-
els and then activated intracellular STAT3 signaling, 
which was diminished by the addition of IL-6 antibod-
ies. We also demonstrated that XBP1s bound to the IL-6 
promoter and activated IL-6 transcription directly. Fur-
thermore, increased expression of IRE1α and XBP1s pro-
moted Mel-RMu cell proliferation, which was dependent 
on secreted extracellular IL-6.
XBP1s, the potent transcription activator and product 
of the RNase activity of IRE1α, mediates the expression 
of a large group of genes, thus relieving ER stress and 
reestablishing ER homeostasis [7–9, 24]. In addition to 
its critical role in ER stress, growing evidence has dem-
onstrated that the IRE1α-XBP1 pathway controls the 
expression of many genes that are involved in the regula-
tion of various biological processes, such as peroxisome 
proliferator-activated receptor alpha (PPARα) [18], pro-
tein disulfide isomerase (PDI) [25], fatty acid synthase 
(Fasn), and UDP-galactose-4-epimerase [26]. The IRE1α-
XBP1 pathway also exerts non-transcriptional actions 
such as promoting the degradation of the forkhead box 
O1 (FoxO1) protein [27]. XBP1s was also found to acti-
vate IL-6 transcription by binding to its promoter in 
murine macrophages involved in innate immunity [28]. 
Moreover, Toosi et al. have reported that vitiligo-induced 
activation of UPR pathways upregulates the expression 
of IL-6 and IL-8 in melanoma cells, but the molecular 
mechanism is not clearly defined [29]. Here, we demon-
strated that XBP1s activated IL-6 expression by binding 
to its promoter in human melanoma cells, thus indicat-
ing the conservation of XBP1 behavior in controlling IL-6 
expression. Inhibition of the RNase activity of IRE1α by 
4μ8C impaired IL-6 expression induced by the activation 
of the IRE1α-XBP1 pathway. Because IL-6 is considered 
to be a critical player in promoting cell proliferation [30] 
and progression and even a prognostic biomarker [30, 
31] of melanoma, the RNase activity of IRE1α may be a 
promising therapeutic target.
Recently, Liu et al. have reported that IRE1α promotes 
hepatocyte proliferation and liver regeneration by regu-
lating the STAT3 signaling pathway [32]. Although IRE1α 
has been implicated in cell proliferation in pancreatic 
islet cells [33] and certain cancer cell lines [34], it remains 
unclear whether the IRE1α-XBP1 branch is linked to 
melanoma cell growth. Our work is the first to demon-
strate the critical role of IRE1α-XBP1s in promoting cell 
proliferation of melanoma and its detailed molecular 
mechanism.
Constitutive activation of STAT3 signaling has been 
observed in aggressive forms of cancer and is crucial in 
regulating tumor cell proliferation and survival in diverse 
cancer types [15, 35, 36]. Previous studies have revealed 
that STAT3 is constitutively activated in approximately 
50–90% of melanomas [37, 38], but the exact details 
were unknown. Our results suggested that in melanoma 
cells, the constitutive activation of STAT3 is activated by 
secreted extracellular IL-6 working in an autocrine/par-
acrine manner, which can be abolished by adding IL-6 
antibodies to the medium, thus neutralizing IL-6. Above 
all, IL-6 neutralization attenuated the enhanced prolifer-
ation of melanoma cells induced by the activation of the 
IRE1α-XBP1 branch, thus suggesting that anti-IL-6 anti-
body is a promising candidate for the clinical treatment 
of melanoma.
Conclusion
In summary, our results reveal a novel role of the IRE1α-
XBP1 branch of UPR pathways in regulating Mel-RMu 
cell proliferation and progression via controlling IL-6 
expression and STAT3 signaling. However, in vivo studies 
are needed to clarify the high rate of melanoma cell pro-
liferation caused by the constitutive activation of STAT3 
signaling resulting from XBP1s-driven IL-6 expression. 
Our study provides a new promising therapeutic target 
for melanoma treatment and drug discovery.
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